New Data Help Size Up Novel Class Of SGLT-2 Inhibitors In Diabetes
Executive Summary
Though probable class side effects of urinary tract and genital infections remain worrisome, SGLT-2 inhibitors nevertheless have potential as add-ons to multiple kinds of diabetes drugs, based on data released at the recent American Diabetes Association meeting
You may also be interested in...
Bristol Outperforms In Q3, But Will Dapagliflozin, Apixaban See It Past Plavix?
The big pharma beats analysts' estimates for the third quarter, but all eyes are turned toward its pipeline as the Plavix patent expiry becomes a near-term reality.
FDA's Dapagliflozin Review To Focus On Hepatic Effects, Cancer Risks
The agency will ask its Endocrinologic and Metabolic Drugs Advisory Committee to weigh these "unexpected" safety findings despite a clean cardiovascular profile for Bristol-Myers Squibb/AstraZeneca's first-in-class diabetes drug.
Boehringer Ingelheim Plays Catch-Up In Diabetes, Close To Filing DPP-4 Drug
As part of its ongoing effort to develop drugs for metabolic disease, Boehringer Ingelheim is gearing up for a filing within the next few months of its first diabetes drug - the DPP-4 inhibitor linagliptin